Transfer Factor Immunotherapy of Rheumatoid Arthritis

Transfer factor: A potential agent for immunotherapy of cancer

“…Curiously, there has been a poor correlation between clinically observed responses, results of skin reactivity tests, and these in vitro laboratory tests. Experience has shown that in the face of clinically unsuccessful treatment, one or more of the laboratory indicators may [47,53] or may not [45,47,53,56,58] decrease or turn out negative, while the skin reactivity remains negative [59] or increases [56,59]. Conversely, in patients who have responded to TF therapy, skin test reactivity has increased in some patients [51-53, 59, 60] but decreased in others [53,59], and in vitro laboratory tests have yielded higher [36,39,47,52,53,58] or lower values [45,57,53].…”

“…However, some researchers [22,53] have made use of readily accessible blood bank leukocytes which, by definition, could not be expected to contain the capacity to transfer specific reactivity. The majority of researchers have selected as donors patients in remission [52,54], household contacts [30,36,39,47,52,59], or individuals with a history of etiologically related illness [50,51]. These donors are presumed to have or were demonstrated by in vitro assay to have lymphocytes reactive to the tumor antigens in question.…”